TG Therapeutics, Inc.
787 Seventh Avenue
48th Floor
New York
New York
10019
United States
Tel: 212-554-4484
Fax: 212-554-4531
Website: http://www.tgtherapeutics.com/
Email: ir@tgtxinc.com
367 articles with TG Therapeutics, Inc.
-
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
3/31/2023
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of BRIUMVI™ (ublituximab-xiiy) for the treatment of adult patients relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
3/3/2023
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Massachusetts.
-
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
2/28/2023
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company developments.
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business UpdateConference call to be held Tuesday, February 28, 2023 at 8:30 AM ET
2/24/2023
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, February 28, 2023 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2022 and provide a business outlook for 2023.
-
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/24/2023
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab-xiiy) in adult patients with relapsing forms of multiple sclerosis (RMS), presented at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2/14/2023
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California.
-
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
1/26/2023
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
-
TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferencePresentation scheduled for Monday, January 9, 2023 at 9:45 AM PT
1/6/2023
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA.
-
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
12/28/2022
TG Therapeutics, Inc. announced the U.S. Food and Drug Administration has approved BRIUMVI™, for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
-
TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/10/2022
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments, along with a business outlook for the remainder of 2022.
-
TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business UpdateConference call to be held Thursday, November 10, 2022 at 8:30 AM ET
11/8/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results for the third quarter of 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
-
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
10/26/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
-
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
10/13/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming 2022 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held October 26 – 28, 2022, in Amsterdam, the Netherlands.
-
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/9/2022
TG Therapeutics, Inc., announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate virtually in a fireside chat at the H.C. Wainwright Global Investment Conference taking place September 12 – 14, 2022.
-
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
-
TG Therapeutics announced the publication of Phase III trials of relapsing/remitting multiple sclerosis (RMS) drug candidate in the NEJM.
-
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
8/25/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced results from the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company’s investigational anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis (RMS), were published in The New England Journal of Medicine (NEJM).
-
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsConference call to be held today, August 8, 2022 at 8:30 AM ET
8/8/2022
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments, along with a business outlook for the remainder of 2022.
-
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business UpdateConference call to be held Monday, August 8, 2022 at 8:30 AM ET
8/5/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 AM ET to discuss results for the second quarter of 2022.
-
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
6/27/2022
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS).